{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:52:56Z","timestamp":1791377576321,"version":"4.3.2"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007911","name":"University of California San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejmech.2021.113569","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T10:56:01Z","timestamp":1622285761000},"page":"113569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["A first-in-class anticancer dual HDAC2\/FAK inhibitors bearing hydroxamates\/benzamides capped by pyridinyl-1,2,4-triazoles"],"prefix":"10.1016","volume":"222","author":[{"given":"Muhamad","family":"Mustafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer Ali","family":"Abd El-Hafeez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Abdelhamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gajanan D.","family":"Katkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser A.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8917-3201","authenticated-orcid":false,"given":"Pradipta","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa M.","family":"Hayallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal El-Din A.","family":"Abuo-Rahma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113569_bib1","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery: miniperspective","volume":"57","author":"Anighoro","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib2","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/med.21505","article-title":"Chimeric HDAC inhibitors: comprehensive review on the HDAC-based strategies developed to combat cancer","volume":"38","author":"Hesham","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.113569_bib3","doi-asserted-by":"crossref","first-page":"112322","DOI":"10.1016\/j.ejmech.2020.112322","article-title":"Design, synthesis and biological evaluation of novel histone Deacetylase1\/2 (HDAC1\/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer","author":"Yun","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib4","first-page":"112904","article-title":"Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors","author":"kA Bass","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib5","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ejmech.2018.08.073","article-title":"HDAC as onco target: reviewing the synthetic approaches with SAR study of their inhibitors","volume":"158","author":"Sangwan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.bjc.6604199","article-title":"Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy","volume":"98","author":"Weichert","year":"2008","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejmech.2021.113569_bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-0463.2005.apm_04.x","article-title":"Increased expression of histone deacetylase 2 is found in human gastric cancer","volume":"113","author":"Song","year":"2005","journal-title":"Apmis"},{"key":"10.1016\/j.ejmech.2021.113569_bib8","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1245\/s10434-010-1182-1","article-title":"Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer","volume":"17","author":"Mutze","year":"2010","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.ejmech.2021.113569_bib9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.biopha.2016.09.030","article-title":"HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin","volume":"84","author":"Li","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2021.113569_bib10","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3892\/or.2015.4263","article-title":"HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population","volume":"34","author":"Ler","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2021.113569_bib11","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00204-018-2229-5","article-title":"The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells","volume":"92","author":"Kiweler","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejmech.2021.113569_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028103","article-title":"Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1\/S cell cycle proteins","volume":"6","author":"Noh","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113569_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","article-title":"Inhibition of histone deacetylase 2 increases apoptosis and p21 Cip1\/WAF1 expression, independent of histone deacetylase 1","volume":"12","author":"Huang","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2021.113569_bib14","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3892\/etm.2015.2745","article-title":"Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase\/Akt pathway","volume":"10","author":"Kong","year":"2015","journal-title":"Experimental and therapeutic medicine"},{"key":"10.1016\/j.ejmech.2021.113569_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40360-018-0255-9","article-title":"Artesunate may inhibit liver fibrosis via the FAK\/Akt\/\u03b2-catenin pathway in LX-2 cells","volume":"19","author":"Lv","year":"2018","journal-title":"BMC Pharmacology and Toxicology"},{"key":"10.1016\/j.ejmech.2021.113569_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-41842-6","article-title":"HDAC1 and HDAC2 independently regulate common and specific intrinsic responses in murine enteroids","volume":"9","author":"Gonneaud","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113569_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-016-0157-7","article-title":"Integrin-FAK signaling rapidly and potently promotes mitochondrial function through STAT3","volume":"14","author":"Visavadiya","year":"2016","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2021.113569_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1478-811X-11-35","article-title":"Inhibition of a novel specific neuroglial integrin signaling pathway increases STAT3-mediated CNTF expression","volume":"11","author":"Keasey","year":"2013","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2021.113569_bib19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3802\/jgo.2010.21.4.262","article-title":"The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells","volume":"21","author":"Jin","year":"2010","journal-title":"Journal of gynecologic oncology"},{"key":"10.1016\/j.ejmech.2021.113569_bib20","doi-asserted-by":"crossref","first-page":"10299","DOI":"10.1021\/acs.jmedchem.8b01487","article-title":"Discovery of the first-in-class dual histone deacetylase\u2013proteasome Inhibitor","volume":"61","author":"Bhatia","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib21","doi-asserted-by":"crossref","first-page":"112831","DOI":"10.1016\/j.ejmech.2020.112831","article-title":"Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment","volume":"208","author":"Peng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2021.113569_bib23","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ijc.29522","article-title":"Targeting FAK scaffold functions inhibits human renal cell carcinoma growth","volume":"137","author":"B\u00e9raud","year":"2015","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejmech.2021.113569_bib24","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.0c01248","article-title":"Progress in the development of small molecular inhibitors of focal adhesion kinase (FAK)","author":"Lu","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib25","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1021\/acs.jmedchem.6b00487","article-title":"Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK)","volume":"59","author":"Ott","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib26","doi-asserted-by":"crossref","first-page":"127965","DOI":"10.1016\/j.bmcl.2021.127965","article-title":"Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton","volume":"40","author":"Mustafa","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113569_bib27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejmech.2017.09.063","article-title":"Synthesis, antiproliferative, anti-tubulin activity, and docking study of new 1, 2, 4-triazoles as potential combretastatin analogues","volume":"141","author":"Mustafa","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib28","doi-asserted-by":"crossref","first-page":"111697","DOI":"10.1016\/j.ejmech.2019.111697","article-title":"Potent combretastatin A-4 analogs containing 1, 2, 4-triazole: synthesis, antiproliferative, anti-tubulin activity, and docking study","volume":"183","author":"Mustafa","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib29","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1007\/s00044-012-0306-5","article-title":"Synthesis, molecular modeling, and biological evaluation of 1, 2, 4-triazole derivatives containing pyridine as potential anti-tumor agents","volume":"22","author":"Zhang","year":"2013","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2021.113569_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejmech.2018.01.021","article-title":"Spirohydantoins and 1, 2, 4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: design, synthesis, and biological evaluation","volume":"146","author":"Aboeldahab","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ejmech.2016.01.013","article-title":"Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in\u00a0vitro and in\u00a0vivo anti-tumor efficacy","volume":"109","author":"Wen","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib32","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1021\/jm5008962","article-title":"Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors","volume":"57","author":"Tang","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib33","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bmcl.2016.01.022","article-title":"Dissecting structure\u2013activity-relationships of crebinostat: brain penetrant HDAC inhibitors for neuroepigenetic regulation","volume":"26","author":"Ghosh","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113569_bib34","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jid.2015.12.023","article-title":"Sustained Akt activity is required to maintain cell viability in seborrheic keratosis, a benign epithelial tumor","volume":"136","author":"Neel","year":"2016","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2021.113569_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2013.11.006","article-title":"1, 2, 4-Triazole\/oxime hybrids as new strategy for nitric oxide donors: synthesis, anti-inflammatory, ulceroginicity and antiproliferative activities","volume":"71","author":"Abuo-Rahma","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bioorg.2017.03.005","article-title":"Design, synthesis, docking studies and biological evaluation of novel chalcone derivatives as potential histone deacetylase inhibitors","volume":"72","author":"Mohamed","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-8-381","article-title":"Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer","volume":"8","author":"Fritzsche","year":"2008","journal-title":"BMC Canc."},{"key":"10.1016\/j.ejmech.2021.113569_bib38","first-page":"203","article-title":"The role of HDACs as leukemia therapy targets using HDI","volume":"9","author":"Ahmadzadeh","year":"2015","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"10.1016\/j.ejmech.2021.113569_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064600","article-title":"HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure","volume":"8","author":"Stypula-Cyrus","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2021.113569_bib40","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/0008-5472.CAN-08-3937","article-title":"Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis","volume":"69","author":"Barbero","year":"2009","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2021.113569_bib41","first-page":"1125","article-title":"Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways","volume":"16","author":"Shankar","year":"2005","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2021.113569_bib42","doi-asserted-by":"crossref","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","article-title":"Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability","volume":"288","author":"Lauffer","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113569_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003800","article-title":"Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation","volume":"3","author":"Lietha","year":"2008","journal-title":"PloS One"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421004189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421004189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:26:54Z","timestamp":1759328814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421004189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":43,"alternative-id":["S0223523421004189"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113569","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-class anticancer dual HDAC2\/FAK inhibitors bearing hydroxamates\/benzamides capped by pyridinyl-1,2,4-triazoles","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113569"}}